ReviewActa endocrinologica (Bucharest, Romania : 2005)
IMPLICATION OF GUT MICROBIOTA IN DIABETES MELLITUS AND OBESITY.
Review in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Perinatal phlorizin alleviates maternal high-fat diet-induced metabolic syndrome in female mouse offspring and is associated with modulation of the gut microbiota.Frontiers in nutrition · 2026Article
- Article
- Silicon-Enriched Meat Ameliorates Diabetic Dyslipidemia by Improving Cholesterol, Bile Acid Metabolism and Ileal Barrier Integrity in Rats with Late-Stage Type 2 Diabetes.International journal of molecular sciences · 2024Article
- Harnessing Prebiotics to Improve Type 2 Diabetes Outcomes.Nutrients · 2024Review
- Suppression of certain intestinal microbiota metabolites may lead to gestational diabetes in mice fed a high-fat diet.Frontiers in microbiology · 2024Article
- Effect ofNutrients · 2023Article
- Influence ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Gut microbiota, an emergent target to shape the efficiency of cancer therapy.Exploration of targeted anti-tumor therapy · 2023Review
- Bile acids and microbes in metabolic disease.World journal of gastroenterology · 2022Review
- Bone loss is ameliorated by fecal microbiota transplantation through SCFA/GPR41/ IGF1 pathway in sickle cell disease mice.Scientific reports · 2022Article
- Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation.CPT: pharmacometrics & systems pharmacology · 2022Article
- Microbial metabolites: cause or consequence in gastrointestinal disease?American journal of physiology. Gastrointestinal and liver physiology · 2022Review
- Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice.Cancers · 2022Review
- Microbiota Composition and Diversity in Weight Loss Population After the Intake of IQP-AE-103 in a Double-Blind, Randomized, Placebo-Controlled Study.Frontiers in nutrition · 2022Article
- Editorial: Host-microbe interaction and coevolution.Frontiers in genetics · 2022Article
- CRISPR-Cas Technology: Emerging Applications in Clinical Microbiology and Infectious Diseases.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Chains of evidence from correlations to causal molecules in microbiome-linked diseases.Nature chemical biology · 2021Review
- The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review.Cancers · 2021Review
- Review
- Addition of Probiotics to Anti-Obesity Therapy by Percutaneous Electrical Stimulation of Dermatome T6. A Pilot Study.International journal of environmental research and public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsDifferences in the composition of the species of microorganisms in the gut may predict the evolution toward obesity and diabetes mellitus. We carried out a systematic review of the studies dedicated to the role of gut microbiota in diabetes mellitus and obesity.
methodsA systematic literature search of electronic databases was performed, using the search syntax: "Gut microbiota and diabetes and obesity"; abstracts in English, with data about mechanisms of pathogenesis and treatment options by changing the gut composition were included (259 articles). Studies were excluded if they did not have an abstract, or they contained no data about the exact implication mechanism of microbiota.
resultsThere are differences regarding the composition of the gut microbiota in healthy people and type 2 diabetes mellitus patients; the later proved to have significantly decreased Clostridium components, and increased Lactobacillus and Bifidobacterium populations.The intestines of obese subjects are less rich in microbial genes, have a reduced amount of Bacteroidetes and an increased amount of Firmicutes. Fecal microbiota transplantation from obese subjects resulted in adoption of the donor somatotype. Early differences in gut microbiota composition (higher number of Bifidobacteria) function as diagnostic markers for the development of type 2 diabetes mellitus in high-risk patients.The gut endotoxins contribute to metabolic syndrome manifestation. Experimental studies with prebiotic showed lower levels of cytokines and antiobesity potential.
conclusionMicrobiota composition and its changes since childhood have an important role in the metabolic syndrome. Any intervention in order to prevent or treat obesity and diabetes mellitus should have as target the gut immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.